晚期前列腺癌男性Wnt通路基因改变的临床意义
本研究利用PROMISE临床基因组数据库回顾性分析1498例晚期前列腺癌患者,193例(12.9%)存在Wnt通路基因改变。Wnt改变组在初诊、首次转移和去势抵抗性前列腺癌(CRPC)阶段肝转移和肺转移患病率均约为非改变组的2倍,且RB1、AR、SPOP、FOXA1、PIK3CA共现改变更常见,但两组总生存和其他临床结局无显著差异。
要点
- 1498例中193例(12.9%)为Wnt改变,肝转移和肺转移患病率约为非Wnt改变组的2倍。
- Wnt改变与RB1、AR、SPOP、FOXA1、PIK3CA共现基因改变增多相关。
- Wnt改变与总生存或mCRPC雄激素受体抑制治疗结局无显著差异。
核心结论
- Wnt改变的晚期前列腺癌患者内脏转移患病率更高,且RB1、AR、SPOP、FOXA1、PIK3CA改变更常见,但Wnt改变与更差生存或治疗结局无关。
研究设计与样本
- 利用前列腺癌精准医学多机构协作项目(PROMISE)临床基因组数据库进行的回顾性分析,共纳入1498例晚期前列腺癌患者。
- CTNNB1或RSPO2激活突变或APC、RNF43、ZNRF3失活突变定义为Wnt改变,缺乏此类改变定义为Wnt非改变。
主要发现
- 1498例中193例(12.9%)为Wnt改变;初诊时肝转移Wnt改变组4.66% vs 非改变组2.15%,肺转移6.22% vs 3.07%。
- 首次转移诊断时肝转移Wnt改变组10.88% vs 非改变组5.29%,肺转移13.99% vs 6.21%。
- CRPC发生时肝转移Wnt改变组11.40% vs 非改变组6.36%,肺转移12.95% vs 5.29%。
- Wnt改变组共现RB1改变10.4% vs 6.2%,AR改变38.9% vs 25.7%,SPOP改变13.5% vs 4.1%,FOXA1改变6.7% vs 2.8%,PIK3CA改变10.9% vs 5.1%。
- 两组在初诊、首次转移、CRPC诊断或mCRPC接受AR抑制治疗后的总生存及其他临床结局方面无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aberrant Wnt signaling has been implicated in prostate cancer tumorigenesis and metastasis in preclinical models but the impact of genetic alterations in Wnt signaling genes in men with advanced prostate cancer is unknown. METHODS: We utilized the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) clinical-genomic database for this retrospective analysis. Patients with activating mutations in CTNNB1 or RSPO2 or inactivating mutations in APC, RNF43, or ZNRF3 were defined as Wnt-altered, while those lacking such alterations were defined as Wnt non-altered. We compared patient characteristics and clinical outcomes as well as co-occurring genetic alterations according to Wnt alteration status. RESULTS: Of the 1498 patients included, 193 (12.9%) were Wnt-altered. These men had a statistically significant 2-fold increased prevalence of liver and lung metastases as compared with Wnt non-altered patients at the time of initial diagnosis, (4.66% v 2.15% ; 6.22% v 3.07%), first metastatic disease diagnosis (10.88% v 5.29%; 13.99% v 6.21%), and CRPC development (11.40% v 6.36%; 12.95% v 5.29%). Wnt alterations were associated with more co-occurring alterations in RB1 (10.4% v 6.2%), AR (38.9% vs 25.7%), SPOP (13.5% vs 4.1%), FOXA1 (6.7% vs 2.8%), and PIK3CA (10.9% vs 5.1%). We found no significant differences in overall survival or other clinical outcomes from initial diagnosis, first metastatic disease, diagnosis of CRPC, or with AR inhibition for mCRPC between the Wnt groups. CONCLUSIONS: Wnt-altered patients with prostate cancer have a higher prevalence of visceral metastases and are enriched in RB1, AR, SPOP, FOXA1, and PIK3CA alterations. Despite these associations, Wnt alterations were not associated with worse survival or treatment outcomes in men with advanced prostate cancer.
引用
- Broderick A, Pan E, Li J, et al. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 39019980. doi:10.1038/s41391-024-00869-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。